Rythmol SR (Atrial Fibrillation) - Analysis and Forecasts to 2022

Introduction

Abstract

Rythmol SR (Atrial Fibrillation) - Analysis and Forecasts to 2022

Summary

GlobalData's pharmaceuticals report, "Rythmol SR (Atrial Fibrillation) - Analysis and Forecasts to 2022" provides Rythmol SR global sales estimates. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2004-2022). The report also includes information on Atrial Fibrillation market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

• Therapy area profile including patient population for the US market
• Analysis and review of Rythmol SR including sales data
• Qualitative and quantitative assessment of market space
• Analysis of the trends, drivers and restraints shaping and defining the markets
• In-depth analysis of Rythmol SR including efficacy, safety, pricing, competition and other details which influence its sales potential
• Global sales forecast for 2004 -2022 for Rythmol SR

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of competition by understanding the changing competitive landscape
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of the drug's performance
• Examine the historical sales performance of a drug in seven major markets
• Obtain sales forecast for currently marketed/pipeline drug for 2011-2022 for all seven major markets

Keywords

Rythmol SR, propafenone, anti-arrhythmics, rapid heartbeats, atrial arrhythmias, ventricular arrhythmias, short-life

Table of Contents

TOC

1 Table of Contents

1 Table of Contents 2

• 1.1 List of Tables 3
• 1.2 List of Figures 3

2 Introduction 4

• 2.1 Atrial Fibrillation Market 4
• 2.2 Epidemiology 4
• 2.3 Etiology and Risk Factors 5
• 2.3.1 Symptoms associated with AF 6
• 2.4 GlobalData Analysis and Forecasts Report Guidance 7

3 Atrial Fibrillation: Market Characterization 8

• 3.1 Atrial Fibrillation Market 8
• 3.2 Atrial Fibrillation Market Forecasts and CAGR 9
• 3.3 Drivers of Atrial Fibrillation Market 9
• 3.3.1 High Unmet need 9
• 3.3.2 Strong Pipeline 10
• 3.3.3 Increase in prevalence and ageing populations 10
• 3.3.4 Organisation of Awareness Campaigns 11
• 3.4 Barriers in Atrial Fibrillation Market 12
• 3.4.1 Limitations in established therapies 12
• 3.4.2 High cost of emerging therapies 12

4 Classification in Atrial Fibrillation: Introduction 13

• 4.1 AF Classification 13
• 4.1.1 Pathophysiology of AF 14
• 4.1.2 Diagnosis in Atrial Fibrillation 15
• 4.1.3 Impact of Atrial Fibrillation 16

5 Treatment Options and Management in Atrial Fibrillation 17

• 5.1 Rate control and Rhythm control 17
• 5.2 Rate Control Versus Rhythm Control 19

6 Rythmol SR 20

• 6.1 Introduction 20
• 6.2 Mechanism of Action 20
• 6.3 Clinical Studies 20
• 6.4 Approval Status of Rythmol SR 21
• 6.5 Factors Affecting Sales of Rythmol SR 21
• 6.5.1 Unique Profile with efficacy, safety and dosing profile 21
• 6.5.2 Entry of Generics 22
• 6.6 Drug Evaluation 22
• 6.6.1 Drug Risk Benefit Score 22
• 6.6.2 Intensity of Competition 23
• 6.7 Sales Forecasts 24
• 6.7.1 Target Patient Pool of Rythmol SR 24
• 6.7.2 Dosing 24
• 6.7.3 Market Penetration 24
• 6.7.4 Annual Cost of Therapy 25
• 6.7.5 Sales Projections of Rythmol SR 26

7 Appendix 27

• 7.1 Market Definitions 27
• 7.2 Abbreviations 27
• 7.3 Research Methodology 27
• 7.3.1 Coverage 27
• 7.3.2 Secondary Research 28
• 7.3.3 Forecasting 28
• 7.3.4 Number of Patients Approved to Take the Drug 28
• 7.3.5 Net Penetration of Drug 29
• 7.3.6 Net Annual Dosing 29
• 7.3.7 Annual Cost of Therapy 29
• 7.4 Drug Sales Estimates Model 29
• 7.5 Contact Us 29
• 7.6 Disclaimer 30
• 7.7 Sources 30

List of Tables

1.1 List of Tables

• Table 1: Epidemiology of Atrial Fibrillation (2011) 5
• Table 2: Increase in the Risk of AF in The Presence of Risk Factors 5
• Table 3: Stratification of All Risk Factors For Atrial Fibrillation 6
• Table 4: Atrial Fibrillation Classification 14
• Table 5: Treatment Guidelines For the Management of Atrial Fibrillation 17
• Table 6: Rythmol SR, Approval Status 21
• Table 7: Drug Risk Benefit Score of Rythmol SR 22
• Table 8: Rythmol SR, Atrial Fibrilation, Global, Cost of Therapy, 2011 25
• Table 9: Rythmol SR, Atrial Fibrillation, The US, Sales Forecasts ($m), 2004-2012 26
• Table 10: Rythmol SR, Atrial Fibrillation, The US, Sales Forecasts ($m), 2013-2022 26

List of Figures

1.2 List of Figures

• Figure 1: Atrial Fibrillation, Global, Market Size Forecasts ($bn), 2011-2022 9
• Figure 2: Percentage Of Molecules (in Different Phases of Development) For Atrial Fibrillation 10
• Figure 3: Increase of Prevalance Population in Atrial Fibrillation 11
• Figure 4: Normal Heart Rhythm Vs Atrial Fibrillation 13
• Figure 5: Broad classification of Patterns in Atrial Fibrillation 14
• Figure 6: Disease States Associated with Atrial Fibrillation, By (%) 15
• Figure 7: Therapeutic Goals in Patients with Atrial Fibrillation (AF) 18
• Figure 8: Management of Newly Discovered Atrial Fibrillation (AF) 18
• Figure 9: Drug Model Diagram of Rythmol SR 24
• Figure 10: Rythmol SR, Atrial Fibrillation, The US, Sales Forecasts ($m), 2004-2022 26
• Figure 11: Patients Approved for the Drug 28

Rythmol SR (Atrial Fibrillation) - Analysis and Forecasts to 2022 published by GlobalData in May 31, 2012. This report consists of Pages: 30 and the price starts from US $ 2000.